ТИРОНЕТ – все о щитовидной железе Для специалистов Журнал Тиронет 2011 год № 2

Тиреостатические препараты

Луиджи Барталена
Перевод В.В. Фадеева

Список литературы

  1. Brent GA. Clinical Practice – Graves’ Disease. N Engl J Med 2008; 358: 2594-2605.
  2. Hegedus L. Treatment of Graves’ hyperthyroidism: evidence-based and emerging modalities. Endocrinol Metab Clin N Am 2009; 38: 355-371.
  3. van Soestbergen MJ, van der Vijver JC, Graafland AD. Recurrence of hyperthyroidism in multinodular goiter after long-term drug therapy: a comparison with Graves’ disease. J Endocrinol Invest 1992; 15: 797-800.
  4. Emiliano AB, Governale L, Parks M, Cooper DS. Shifts in propylthiouracil and methimazole prescribing practices: antithyroid drug use in the United States from 1991 to 2008. J Clin Endocrinol Metab 2010; 95: 2227-2233.
  5. Jansson R, Dahlberg PA, Lindstrom B. Comparative bioavailability of carbimazole and methimazole. Int J Clin Pharmacol Ther Toxicol 1983; 21: 505.510.
  6. Cooper DS. Antithyroid drugs. N Engl J Med 2005; 352: 905- 917.
  7. Weetman AP. How antithyroid drugs works in Graves’ disease. Clin Endocrinol (Oxf) 1992; 37: 317-318.
  8. Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Torring O. TSH-receptor autoimmunity in Graves’ disease after therapy with antithyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol 2008; 158: 69-75.
  9. Sonnet E, Massart C, Gibassier J, Allannic H, Maugendre D. Longitudinal study of soluble intercellular adhesion molecule-1 (ICAM-1) in sera of patients with Graves’ disease. J Endocrinol Invest 1999; 22: 430-435.
  10. Tsatsoulis A, Vlachoyiannopoulos PG, Dalekos GN, Johnson EO, Moutsopoulos HM. Increased serum interleukin-1 beta during treatment of hyperthyroidism with antithyroid drugs. Eur J Clin Invest 1995; 25: 654-658.
  11. Salvi M, Girasole G, Pedrazzoni M, Passeri M, Giuliani N, Minelli R, Braverman LE, Roti E. Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves’ disease. J Clin Endocrinol Metab 1996; 81: 2976-2979.
  12. Zantut-Wittmann DE, Tambascia MA, da Silva Trevisan MA, Pinto GA, Vas-sallo J. Antithyroid drugs inhibit in vivo HLA- DR expression in thyroid follicular cells in Graves’ disease. Thyroid 2001; 11: 575-580.
  13. Bartalena L, Bogazzi F, Martino E: Adverse effects of thyroid hormone preparations and antithyroid drugs. Drug Safety 1996 15: 53-63.
  14. Ahmed K, Rao S, Simha V. ANCA-positive vasculitis in a patient with Graves’ disease: cross-reaction between propylthiouracil and methimazole. Endocr Pract 2010; 9: 1-11.
  15. Sheng WH, Hung CC, Chen YC, Fang CT, Hsieh SM, Chang SC, Hsieh WC. Antithyroid drug-induced agranulocytosis complicated by life-threatening infections. QJM 1999; 92: 455-461.
  16. Andres E, Kutz JE, Perrin AE, Dufour P, Schlienger JL, Maloisel F. Haematopoietic growth factor in antithyroid drug-induced agranulocytosis. QJM 2001; 94: 423-428.
  17. Takata K, Kubota S, Fukata S, Kudo T, Nishihara E, Ito M, Amino N, Miyauchi A. Methimazole-induced agranulocytosis in patients with Graves’ disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily. Thyroid 2009; 19: 559-563.
  18. Pearce SH. Spontaneous reporting of adverse reactions to carbimazole and propylthiouracil in the UK. Clin Endocrinol (Oxf) 2004; 61: 589-594.
  19. Franklyn JA. Antithyroid therapy – best choice of drug and dose. Nature Rev Endocrinol 2009; 5: 592-594.
  20. Mandel SJ, Cooper DS. The use of antithyroid drugs in pregnancy and lactation. J Clin Endocrinol Metab 2001; 86: 2354- 2359.
  21. Karlsson FA, Axelsson O, Melhus H. Severe embryopathy and exposure to methimazole in early pregnancy. J Clin Endocrinol Metab 2001; 87: 947-948.
  22. Cooper DS, Rivkees SA. Putting propylthiouracil in perspective. J Clin Endocrinol Metab 2009; 94: 1881-1882.
  23. Bahn RS, Burch HS, Cooper DS, Garber JR, Greenlee CM, Klein IL, Laurberg P, McDougall IR, Rivkees SA, Ross D, Sosa JA, Stan MN. The role of propylthiouracil in the management of Graves’ disease in adults: report of a joint meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid 2009; 7: 673-674.
  24. Harper L, Chin L, Daykin J, Allahabadia A, Heward J, Gough SC, Savage CO, Franklyn JA. Propylthiouracil and carbimazoleassociated antineutrophil cytoplasmic antibodies (ANCA) in patients with Graves’ disease. Clin Endocrinol (Oxf) 2004; 60: 671-675.
  25. Cin MO, Gursoy A, Morris Y, Aydintug OT, Kamel N, Gullu S. Prevalence and clinical significance of antineutrophil cyto- plasmic antibody in Graves’ patients treated with propylthiouracil. Int J Clin Pract 2009; 63: 299-302.
  26. Abraham P, Avenell A, McGeosch SC, Clark LF, Bevan JS. Antithyroid drug regimen for treating Graves’ hyperthyroidism. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003420. DOI: 10.1002/14651858.CD003420. pub4.
  27. Cooper DS. Propylthiouracil levels in hyperthyroid patients unresponsive to large doses. Evidence of poor patient compliance. Ann Intern Med 1985; 102: 328-331.
  28. Razvi S, Vaidya B, Perros P, Pearce SHS. What the evidence behind the evidence-base? The premature death of block- replace antithyroid drug regimens for Graves’ disease. Eur J Endocrinol 2006; 154: 783-786.
  29. Hashizume K, Ichikawa K, Sakurai A, Suzuki S, Takeda T, Kobayashi M, Miyamoto T, Arai M, Nagasawa T. Administration of thyroxine in treated Graves’ disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N Engl J Med 1991; 324: 947-953.
  30. McIver B, Rae P, Beckett G, Wilkinson E, Gold A, Toft A. Lack of effect of thyroxine in patients with Graves’ hyperthyroidism who are treated with an antithyroid drug. N Engl J Med 1996; 334: 220-224.
  31. Lucas A, Salinas I, Rius F, Pizarro E, Granada ML, Foz M, Sanmart A. Medical therapy of Graves’ disease: does thyroxine prevent recurrence of hyperthyroidism? J Clin Endocrinol Metab 1997; 82: 2410-2413.
  32. Rittmaster RS, Abbott EC, Douglas R, Givner ML, Lehmann L, Reddy S, Salisbury SR, Shlossberg AH, Tan MH, York SE. Effect of methimazole, with or without L-thyroxine, on remission rates in Graves’ disease. J Clin Endocrinol Metab 1998; 83: 814-818.
  33. Raber W, Kmen E, Waldhausl W, Vierhapper H. Medical therapy of Graves’ disease: effect on remission rates of methimazole alone and in combination with triiodothyronine. Eur J Endocrinol 2000; 142: 117-124.
  34. Glinoer D, de Nayer P, Bex M And The Belgian Collaborative Study Group on Graves’ Disease: Effects of L-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves’ hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study. Eur J Endocrinol 2001; 144: 475-483.
  35. Nedrebo BG, Holm PI, Uhlving S, Sorheim JI, Skeie S, Eide GE, Husebye ES, Lien EA, Aanderyd S. Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves’ disease. Eur J Endocrinol 2002; 147: 583-589.
  36. Hoermann R, Quadbeck B, Roggenbuck U, Szabolcs I, Pfeilschifter J, Meng W, Reschke K, Kackenberg K, Dettman J, Prehn B, Hirche H, Mann K & Basedow Study Group. Relapse of Graves’ disease after successful outcome of antithyroid drug therapy: results of a prospective randomized study on the use of levothyroxine. Thyroid 2002; 12: 1119-1128.
  37. Grebe SKG, Feek CM, Ford HC, Fagerstrom JN, Cordwell DP, Delahunt JW, Toomath RJ. A randomized trial of short-term treatment of Graves’ disease with high-dose carbimazole plus thyroxine versus low-dose carbimazole. Clin Endocrinol (Oxf.) 1998; 48: 585-592.
  38. Weetman AP, Pickerill AP, Watson P, Chatterjee VK, Edwards OM. Treatment of Graves’ disease with the block-replace regimen of antithyroid drugs: the effect of treatment duration and immunogenetic susceptibility on relapse. QJM 1994; 87: 337-341.
  39. Azizi F, Ataie L, Hedayati M, Mehrabi Y, Sheikholeslami F. Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine. Eur J Endocrinol 2005; 152: 685-701.
  40. Laurberg P, Andersen S, Karmisholt J. Antithyroid drug therapy of Graves’ hyperthyroidism: realistic goals and focus on evidence. Expert Rev Endocrinol Metab 2006; 1: 91-102.
  41. Mazza E, Carlini M, Flecchia D, Blatto A, Zuccarini O, Gamba S, Beninati S, Messina M. Long-term follow-up of patients with hyperthyroidism due to Graves’ disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs. continuous treatment with low methimazole doses: a retrospective study. J Endocrinol Invest 2008; 31: 866-872.
  42. Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, Rocchi R, Martino E, Pinchera A. Clinical features of patients with Graves’ disease undergoing remission after antithyroid drug treatment. Thyroid 1997; 7: 369-375.
  43. Wood LC, Ingbar SH. Hypothyroidism as a late sequel in patients with Graves’ disease treated with antithyroid agents. J Clin Invest 1979; 64: 1429-1436.
  44. Bartalena L, Marcocci C, Lai A, Tanda ML. Graves’ hyperthyroidism of recent onset and Graves’ orbitopathy: to ablate or not to ablate the thyroid? J Endocrinol Invest 2008; 31: 578-581.
  45. Allahabadia A, Daykin J, Holder RL, Sheppard MC, Gough SCL, Franklyn JA. Age and gender predict the outcome of treatment for Graves’ hyperthyroidism. J Clin Endocrinol Metab 2000; 85: 1038-1042.
  46. Kimball LE, Kulinskaya E, Brown B, Johnston C, Farid NR. Does smoking increase relapse rates in Graves’ disease? J Endocrinol Invest 2002; 25: 152-157.
  47. Fukao A, Takamatsu J, Murakami Y, Sakane S, Miyauchi A, Kuma K, Hayashi S, Hanafusa T. The relationship of psychological factors to the prognosis of hyperthyroidism in antithyroid drug-treated patients with Graves’ disease. Ciin Endocrinol (Oxf) 2003; 58: 550-555.
  48. Laurberg P, Bournaud C, Karmisholt J, Orgiazzi J. Management of Graves’ hyperthyroidism in pregnancy: focus on both maternal and foetal thyroid function, and caution against surgical thyroidectomy in pregnancy. Eur J Endocrinol 2009; 160: 1-8.
  49. Negro R, Beck-Peccoz P, Chiovato L, Garofalo P, Guglielmi R, Papini E, Tonacchera M, Vermiglio F, Vitti P, Zini M, Pinchera A. Hyperthyroidism and pregnancy. An Italian Thyroid Association (AIT) and Italian Association of Clinical Endocrinologists (AME) joint statement for clinical practice. J Endocrinol Invest 2011; 34: 225-231.
  50. Krassas GE, Poppe K, Glinoer D. Thyroid function and human reproductive health. Endocr Rev 2010; 31: 702-755.
  51. Chan GW, Mandel SJ. Therapy insight: management of Graves’ disease during pregnancy. Nat Clin Pract Endocrinol Metab 2007; 3: 470-478.
  52. Lazarus JH. Thyroid disease during pregnancy. In: Krassas GE, Rivkees SA, Kiess W, eds. Disease of the thyroid in childhood and adolescence (pediatric and adolescent medicine), vol 11, 2007, Basel: Karger, 25-43.
  53. Galofre JC, Davies TF. Autoimmune thyroid disease in pregnancy: a review. J Womens Health (Larchmt)2009; 18: 1847-1856.
  54. Mortimer R, Cannell GR, Addison R, Johnson LP, Roberts MS, Bernus I. Methimazole and propylthiouracil equally cross the perfused human term placental lobule. J Clin Endocrinol Metab 1997; 82: 3099-3102.
  55. Foulds N, Walpole I, ElmslieF, Mansour S. Carbimazole embryopathy: an emerging phenotype. Am J Med Genet 2005; 132A: 130-135.
  56. Barbero P, Ricagni C, Mercado G, Bronberg R, Torrado M. Choanal atresia associated to prenatal methimazole exposure: three new patients. Am J Med Genet 129A: 83-86.
  57. Clementi M, Di Gianantonio E, Cassina M, Leoncini E, Botto LD, Mastroiacovo P and the SAFE-Med Study Group. Treatment of hyperthyroidism in pregnancy and birth defects. J Clin Endocrinol Metab 2010; 95: E337-E341.
  58. Rivkees SA. The treatment of Graves’ disease in children. J Pediatr Endocrinol Metab 2006; 9: 1095-1111.
  59. Lippe BM, Landaw EM, Kaplan SA. Hyperthyroidism in children treated with long term medical therapy: twenty-five percent remission every two years. J Clin Endocrinol Metab 1987; 64: 1241-1247.
  60. Rivkees SA, Dinauer C. An optimal treatment for pediatric Graves’ disease is radioiodine. J Clin Endocrinol Metab 2007; 92: 797-800.
  61. Lee JA, Grumbach MM, Clark OH. The optimal treatment for pediatric Graves’ disease is surgery. J Clin Endocrinol Metab 2007; 92: 801-803.
  62. Rivkees SA, Szarfman A. Dissimilar hepatoxicity profiles of propylthiouracil and methimazole in children. J Clin Endocrinol Metab 2010; 95: 3260-3267.
  63. Rivkees SA, Mattison DR. Ending propylthiouracil-induced liver failure in children. N Engl J Med 2009; 360: 1574-1575 (letter).
  64. McKenzie JM, Zakarjia M. Fetal and neonatal hyperthyroidism and hypothyroidism due to maternal TSH receptor antibodies. Thyroid 1992; 2: 155-161.
  65. Patil-Sisodia K, Mestman JH. Graves’ hyperthyroidism and pregnancy: a clinical update. Endocr Pract 2010; 16: 118-129.
  66. Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H, Taube A. Occurrence of ophthalmopathy after treatment for hyperthyroidism. N Engl J Med 1992; 326: 1733-1738.
  67. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell’Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E, Pinchera A. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med 1998; 338: 73-78.
  68. Acharya SH, Avenell A, Philip S, Burr J, Bevan JS, Abraham P. Radioiodine therapy (RAI) for Graves’ disease (GD) and the effect on ophthalmopathy: a systematic review. Clin Endocrinol (Oxf) 2008; 69: 943-950.
  69. Traisk F, Tallstedt L, Abraham-Nordling M, Andersson T, Berg G, Calissendorff J, Hallengren B, Hedner P, Lantz M, Nystrom E, Ponjavic V, Taube A, Torring O, Wallin G, Asman P, Lundell G. Thyroid-associated ophthalmopathy after treatment for Graves’ hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab 2009; 94:3700-3707.
  70. Tallstedt L, Lundell G, Blomb erg H, Bring J. Does early administration of thyroxine reduce the development of Graves’ ophthalmopathy after radioiodine treatment? Eur J Endocrinol 1994; 130: 494-497.
  71. Bartalena L , Marcocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A. Use of corticosteroids to prevent progression of Graves’ ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 1989; 321:1349-1352.
  72. Tanda ML , Lai A, Bartalena L. Rel ation between Graves’ orbitopathy and radioiodine therapy for hyperthyroidism: facts and unsolved questions. Cli n Endocrinol (Oxf) 2008; 69: 845-847.
  73. Lai A, Sassi L, Compri E, Marino F, Sivelli P, Piantanida E, Tanda ML, Bartalena L . Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent Graves’ orbitopathy: a retrospective cohort study. J Clin Endocrinol Metab 2010; 95: 1333-1337.
  74. Marcocci C, Bruno-Bossio G, Manetti L, Tanda ML , Miccoli P, Iacconi P, Bartolomei MP, Nardi M, Pinchera A, Bartalena L. The course of Graves’ophthal mopathy is not influenced by near total thyroidectomy: a case-control study. Clin Endocrinol (Oxf) 1999; 51: 503-508.
  75. Bartalena L. The dilemma of how to manage Graves’ hyperthyroidism in patients with associated orbitopathy. J Clin Endocrinol Metab 2011; 96, 592-599.
  76. Bartalena L, Baldeschi L, Dickinson, Eckstein AJ, Kendall-Taylor P, Marcocci C, Mourits M, Perros P, Boboridis K, Boschi A, Curr N, Daumerie C, Kahaly GJ, Krassas GE, Lane CM, Lazarus JH, Marin M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM. Consensus statement of the European Group on Graves’ Orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 2008; 158: 273-285.
  77. Bartalena L, Pinchera A, Marcocci C. Management of Graves’ ophthalmopathy: reality and perspectives. Endocr Rev 2000; 21:168-199.
  78. Bartalena L, Tanda ML. Clinical Practice – Graves’ ophthalmopathy. N Engl J Med 2009; 36o: 994-1001.
  79. Wiersinga WM. Preventing Graves ’ ophthalmopathy. N Engl J Med 1998; 338: 121-122.
  80. Andrade VA, Gross JL, Mai a AL . Effect of methimazole pretreatment on serum thyroid hormone levels after radioactive treatment in Graves’ hyperthyroidism. J Clin Endocrinol Metab 1999; 84: 4012-4016.
  81. Braga M, Walpert N, Burch HB, Solomon BL, Cooper DS. The effect of methimazole on cure rates after radioiodine treatment for Graves’ hyperthyroidism: a randomized cli nical trial. Thyroid 2002;12:135-139
  82. Bonnema SJ, Bennedbaek FN, Veje A, Marving J, Hegedus L . Propylthiouracil before 131I therapy of hyperthyroid diseases: effect on cure rate evaluated by a randomized clinical trial. J Clin Endocrinol Metab 2004; 89:4439-4444.
  83. Alexander EK, Larsen PR. High dose of 131I for the treatment of hyperthyroidism caused by Graves’ disease. J Clin Endocrinol Metab 2002;87:1073-1077.
  84. Bartalena L , Bogazzi F, Pinchera A, Martino E. Treatment with thionamides before radioiodine therapy for hyperthyroidism: yes or no? J Clin Endocrinol Metab 2005;90:256.
  85. Bogazzi F, Bartalena L , Campomori A, Brogioni S, Traino C, De Martino F, Rossi G, Lippi F, Pinchera A, Martino E. Treatment with lithium prevents serum thyroid hormone increase after thionamide withdrawal and radioiodine therapy in patients with Graves’ disease. J Clin Endocrinol Metab 2002; 87: 4490-4495.
  86. Bogazzi F, Giovannetti C, Fessehatsion R, Tanda ML , Campomori A, Compri E, Ceccarelli C, Vitti P, Pinchera A, Bartalena L, Martino E. Impact of lithium on radioactive iodine efficacy for Graves’ disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal. J Clin Endocrinol Metab 2010; 95:201-208.
  87. Sabri O, Zimny M, Schulz G, Schreckenberger M, Reinartz P, Willmes K, Buell U. Success rate of radioiodine therapy in Graves’ disease: the influence of thyrostatic medication. J Clin Endocrinol Metab 1999; 84:1229-1233.
  88. Marcocci C, Gianchecchi D, Masini I, Golia F, Ceccarelli C, Bracci E, Fenzi GF, Pinchera A. A reappraisal of the role of methimazole and other factors on the efficacy and outcome of radioiodine therapy of Graves’ hyperthyroidism. J Endocrinol Invest 1990;13:513-520.
  89. Panzer C, Beazley R, Braverman L. Rapid preoperative preparation for severe hyperthyroid Graves’ disease. J Clin Endocrinol Metab 2004;89:2142-2144.
  90. Nayak B, Burman K. Thyrotoxicosis and thyroid storm. Endocrinol Metab Clin North Am 2006; 35: 663-686.
  91. Martino E, Bartalena L, Bogazzi F, Braverman LE. The effects of amiodarone on the thyroid. Endocr Rev. 2001;22: 240-254.
  92. Bogazzi F, Tomisti L, Rossi G, Dell’Unto E, Pepe P, Bartalena L, Martino E. Glucocorticoidsa are preferable to thionamides as first-line treatment for amiodarone-induced thyrotoxicosis due to destructive thyroiditis:a matched restrospective cohort study. J Clin Endocrinol Metab 2009; 94:3757-3762.
  93. Bogazzi F, Bartalena L, Martino E. Approach to the patient with amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab 2010;95:2529-2535.

Для специалистов

Новостная рассылка

Поиск